BiomX Inc. (PHGE)
PHGE Stock Price Chart
Explore BiomX Inc. interactive price chart. Choose custom timeframes to analyze PHGE price movements and trends.
PHGE Company Profile
Discover essential business fundamentals and corporate details for BiomX Inc. (PHGE) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
13 Mar 2019
Employees
52.00
Website
https://www.biomx.comCEO
Jonathan Eitan Solomon MBA
Description
BiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC). It is developing BX004, a phage therapy for CF patients with chronic Pseudomonas aeruginosa respiratory infections that is in Phase 1b/2a clinical trials. The company's pipeline products also include BX005, a topical phage cocktail, which is in Phase 1/2 clinical study that targets Staphylococcus aureus (S. aureus), a bacteria associated with the manifestation of the disease; and BX003, an orally administered phage cocktail, which is in Phase 1b/2a that targets a bacterial target present in the gut of IBD and PSC patients. In addition, the company engages in the provision of colorectal cancer program that utilizes engineered phage with various payloads, which are administered intravenously to target Fusobacterium nucleatum bacteria residing within the tumor microenvironment. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.
PHGE Financial Timeline
Browse a chronological timeline of BiomX Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 13 May 2026
Upcoming earnings on 13 Nov 2025
EPS estimate is -$0.32.
Earnings released on 13 Aug 2025
EPS came in at $0.19 surpassing the estimated -$0.33 by +157.58%.
Earnings released on 15 May 2025
EPS came in at -$0.33 surpassing the estimated -$0.42 by +21.43%.
Earnings released on 25 Mar 2025
EPS came in at -$1.07 surpassing the estimated -$1.65 by +35.15%.
Earnings released on 14 Nov 2024
EPS came in at -$0.97 falling short of the estimated -$0.60 by -61.67%, while revenue for the quarter reached -$84.00K .
Stock split effective on 26 Aug 2024
Shares were split 1 : 10 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 14 Aug 2024
EPS came in at $0.70 surpassing the estimated -$1.20 by +158.33%.
Earnings released on 20 May 2024
EPS came in at -$1.50 falling short of the estimated -$0.70 by -114.29%, while revenue for the quarter reached -$88.00K .
Earnings released on 3 Apr 2024
EPS came in at -$0.80 surpassing the estimated -$1.10 by +27.27%, while revenue for the quarter reached -$87.00K .
Earnings released on 14 Nov 2023
EPS came in at -$1.30 falling short of the estimated -$1.10 by -18.18%, while revenue for the quarter reached -$89.00K .
Earnings released on 9 Aug 2023
EPS came in at -$1.20 matching the estimated -$1.20, while revenue for the quarter reached -$90.00K .
Earnings released on 15 May 2023
EPS came in at -$2.00 matching the estimated -$2.00, while revenue for the quarter reached -$91.00K .
Earnings released on 29 Mar 2023
EPS came in at -$2.00 surpassing the estimated -$2.50 by +20.00%.
Earnings released on 9 Nov 2022
EPS came in at -$2.30 surpassing the estimated -$2.40 by +4.17%.
Earnings released on 10 Aug 2022
EPS came in at -$2.50 surpassing the estimated -$2.90 by +13.79%.
Earnings released on 11 May 2022
EPS came in at -$2.70 surpassing the estimated -$3.20 by +15.63%.
Earnings released on 30 Mar 2022
EPS came in at -$3.60 falling short of the estimated -$0.28 by -1.17K%.
Earnings released on 15 Nov 2021
EPS came in at -$3.70 falling short of the estimated -$2.50 by -48.00%.
Earnings released on 16 Aug 2021
EPS came in at -$3.00 surpassing the estimated -$3.70 by +18.92%.
Earnings released on 24 May 2021
EPS came in at -$3.50 surpassing the estimated -$3.80 by +7.89%.
Earnings released on 31 Mar 2021
EPS came in at -$3.90 matching the estimated -$3.90.
Earnings released on 12 Nov 2020
EPS came in at -$3.80 .
PHGE Stock Performance
Access detailed PHGE performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.